

Rare Breast Cancer Subtypes: Histological, Molecular, and Clinical Peculiarities

MARIA VITTORIA DIECI,^a ENRICO ORVIETO,^b MASSIMO DOMINICI,^c PIERFRANCO CONTE,^a VALENTINA GUARNERI^a

^aDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; and Istituto Oncologico Veneto IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Padova, Italy; ^bDepartment of Pathology, University Hospital of Padova, Padova, Italy;

^cDepartment of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Modena, Italy

Disclosures of potential conflicts of interest may be found at the end of this article.

Key Words. Mucinous carcinoma • Tubular carcinoma • Medullary carcinoma • Metaplastic carcinoma • Pleomorphic lobular cancer • Cribriform carcinoma

ABSTRACT

Breast cancer encompasses a collection of different diseases characterized by different biological and pathological features, clinical presentation, response to treatments, clinical behavior, and outcome. On the basis of cell morphology, growth, and architecture patterns, breast cancer can be classified in up to 21 distinct histological types. Breast cancer special types, including the classic lobular invasive carcinoma, represent 25% of all breast cancers. The histological diversity of breast carcinomas has relevant prognostic implications. Indeed, the rare breast cancer group includes subtypes with very different prognoses, ranging from the tubular carcinoma, associated with an indolent clinical course, to metaplastic cancer, whose outcome is generally unfavorable. New approaches based on gene expression profiling allow the identification of molecularly defined breast cancer classes, with distinct biological features and clinical behavior. In

clinical practice, immunohistochemical classification based on the expression of human epidermal growth factor receptor 2 and Ki67 is applied as a surrogate of the intrinsic molecular subtypes. However, the identification of intrinsic molecular subtypes were almost completely limited to the study of ductal invasive breast cancer. Moreover, some good-prognosis triple-negative histotypes, on the basis of gene expression profiling, can be classified among the poor-prognosis group. Therefore, histopathological classification remains a crucial component of breast cancer diagnosis. Special histologies can be very rare, and the majority of information on outcome and treatments derives from small series and case reports. As a consequence, clear recommendations about clinical management are still lacking. In this review, we summarize current knowledge about rare breast cancer histologies. *The Oncologist* 2014;19:805–813

Implications for Practice: Breast cancer special histologies encompass a panel of various entities with peculiar clinical behaviors. The rarity of such histotypes has jeopardized an extensive clinical evaluation. A review of current available data may help physicians in their clinical practice; however, the development of clear clinical recommendations is not possible. Decisions on the management of patients with rare breast cancer histologies should derive from careful case-by-case multidisciplinary evaluations.

INTRODUCTION

Breast cancer (BC) heterogeneity can be found at different levels, from the classic histopathological characterization to the more modern molecular classification. Indeed, BC encompasses a collection of different diseases characterized by different biological and pathological features, clinical presentation, response to treatments, clinical behavior, and outcome. Pathologists have been aware of the histological diversity of breast carcinomas for a long time. According to the World Health Organization (WHO) classification, BC can be classified in up to 21 distinct histological types on the basis of cell morphology, growth, and architecture patterns (Fig. 1) [1]. The most common histological type is invasive ductal breast carcinoma of no special type (NST), which includes those

cancers without peculiar features to merit classification in one special type. BC special types, including the classic lobular invasive carcinoma, represent 25% of all breast cancers [2]. The histopathological classification has a prognostic value [3]. Two extreme examples are the tubular carcinoma, associated with an excellent prognosis, and metaplastic cancer, whose outcome is generally unfavorable [4, 5].

Nowadays, tumor biology is the main determinant of breast cancer treatment. On the basis of immunohistochemistry (IHC), BC consists of at least three main groups: hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-positive, and triple-negative disease (HR- and HER2-negative).

Correspondence: Valentina Guarneri, M.D., Ph.D., Department of Surgery, Oncology and Gastroenterology, University of Padova, Istituto Oncologico Veneto IRCCS, via Gattamelata 64, 35100 Padova, Italy. Telephone: 39-049-8215291; E-Mail: valentina.guarneri@unipd.it Received March 11, 2014; accepted for publication June 6, 2014; first published online in *The Oncologist Express* on June 26, 2014. ©AlphaMed Press 1083-7159/2014/\$20.00/0 <http://dx.doi.org/10.1634/theoncologist.2014-0108>




Figure 1. Histological special types of breast cancer. (A): Mucinous carcinoma. (B): Tubular carcinoma. (C): Adenoid cystic carcinoma. (D): Cribriform carcinoma. (E): Medullary carcinoma. (F): Apocrine carcinoma. (G): Lobular pleomorphic carcinoma. (H): Micropapillary carcinoma. (I): Metaplastic spindle cell carcinoma.

Endocrine manipulation is the cornerstone of therapy for HR-positive tumors; anti-HER2 agents combined with chemotherapy or endocrine therapy are the standard treatment for tumors overexpressing HER2. Chemotherapy represents the only approach for the treatment of triple-negative breast cancers, because no targeted therapy is available so far.

More recently, the further segmentation of BC into intrinsic molecular subtypes based on different gene expression profiling has allowed the identification of at least four different subgroups with different prognosis and sensitivity to treatment: luminal, normal-like, HER2-enriched, and basal-like [6]. HR-positive tumors mainly cluster within the luminal subtype, which can be further divided into two entities: Luminal A and Luminal B, with the latter mainly represented by HR+/HER2+ or HR+ tumors with high Ki67 levels [7]. HER2+/HR- tumors and triple-negative tumors mainly cluster within the HER2-enriched and basal-like subgroups, respectively. Despite the fact that BC classification based on routine pathologic parameters such as HR, HER2, and Ki67 does not completely recapitulate the gene expression profiling-based molecular classification, it is nowadays applied in clinical practice as a surrogate for the intrinsic molecular subtype definition [8, 9].

However, this approach still presents some pitfalls. First, intrinsic molecular subtypes were identified on the basis of gene expression profiles. However, in recent years, we have observed an exponential development of high-throughput

technologies and their application in cancer research. The introduction of such techniques has indeed revealed deeper levels of tumor heterogeneity. As an illustration, the integration of gene expression and gene copy number data recently led to the identification of at least 10 different clusters of primary BC, with different prognoses [10]. Thus, molecular classification as a field may be considered a work in progress. Second, the main studies that led to the identification of intrinsic molecular subtypes were almost completely limited to ductal invasive breast cancers of no special type and did not take uncommon histologies into account. Thus, molecular classification is more a description of the heterogeneity of invasive ductal carcinomas rather than an exhaustive representation of the entire BC landscape. From this perspective, a relevant study has been conducted by Weigelt et al. [11]. A panel of BC of special types (including invasive lobular, mucinous, neuroendocrine, apocrine, invasive ductal with osteoclastic giant cells, micropapillary, adenoid cystic, metaplastic, and medullary carcinoma) was analyzed by gene expression profiling. The first relevant finding was that by hierarchical analysis, some of the special types (like micropapillary carcinomas) constituted a distinct and separate cluster of tumors, suggesting a high homogeneity at the molecular level. Moreover, when classified according to the intrinsic molecular classification, each BC special type (except from apocrine carcinoma) fell in one molecular subtype only.

On the other hand, within invasive ductal cancers of no special type and classic invasive lobular cancers, all molecular subtypes were represented, suggesting that each rare histotype is more homogeneous at the transcriptome level than more common entities. This was also confirmed at the genomic level, with the demonstration of similar patterns of gene copy number variations for samples of the same rare histology [12]. In addition, some good-prognosis triple-negative histotypes are classified as basal-like cancers based on gene expression profiling, which is the intrinsic molecular subtype with the worst prognosis [11]. As a consequence, treatment decisions based on molecular features not taking into account histological aspects may erroneously recommend unnecessary aggressive therapies for good-prognosis patients.

The main studies that led to the identification of intrinsic molecular subtypes were almost completely limited to ductal invasive breast cancers of no special type and did not take uncommon histologies into account. Thus, molecular classification is more a description of the heterogeneity of invasive ductal carcinomas rather than an exhaustive representation of the entire BC landscape.

In this review, we examine current knowledge about rare BC histologies from a clinical point of view. In addition, when applicable, evidence about specific genomic drivers of rare BC entities will be also described.

CLINICOPATHOLOGICAL FEATURES OF RARE BC SUBTYPES

Good-Prognosis Group

Typically Hormone Receptor Positive

Pure mucinous carcinoma is characterized by the production of abundant extracellular and/or intracellular mucin. The definition of pure mucinous carcinoma consists of nests of tumor cells floating in lakes of mucin, whereas the mixed form also contains common infiltrating ductal carcinoma NST [13–15]. A precisely defined threshold in the percentage of mucinous component for the distinction between pure and mixed mucinous carcinoma is not well established. However, pure mucinous carcinomas are generally defined as containing more than 90% of mucin, and mixed mucinous carcinomas are those containing 50%–90% of mucin [16]. The presence of less than 50% of mucin identifies ductal carcinoma with a mucinous component. Pure mucinous carcinoma accounts for 1%–4% of all breast cancers, and it is generally diagnosed at older ages. In a retrospective series of 11,400 cases of pure mucinous carcinoma, the median age at diagnosis was 71 years versus 61 years observed in patients with infiltrative ductal carcinomas [17].

The most common mammographic appearance of pure mucinous carcinoma is a low-density mass lesion with well-defined margins. On the sonographic examination, these lesions present isoechogetic echo texture relative to subcutaneous fat [18].

These lesions are mostly well-differentiated HR+ and HER2–. The axillary lymph nodes are rarely involved. These features account for the favorable prognosis of this BC

subtype, with a 5-year BC-specific survival rate of 94% compared with 82% of the infiltrating ductal carcinoma counterpart. The overall more favorable outcome is maintained over very prolonged follow-up. The 10-, 15-, and 20-year survival rates were 89%, 85%, and 81%, respectively, for pure mucinous cases compared with 72%, 66%, and 62%, respectively, for infiltrating ductal carcinoma cases [17]. In a large cohort including more than 1,200 cases, the 5-year overall survival (OS) of patients with mucinous carcinoma was not different from the OS of females from the age-matched general population [19].

Tubular carcinoma accounts for less than 2% of invasive breast cancers [20]. For the definition of pure tubular carcinoma, at least 90% of the tumor should present tubular architecture, composed of small round or oval tubules of single layer of epithelial cells that abut directly onto the adjacent desmoplastic stroma. These lesions are usually detected by screening mammography. The radiological appearance is a small spiculated mass that mimics infiltrating ductal carcinoma or radial scars [21].

Tubular carcinomas are nearly always hormone receptor-positive and well-differentiated, with low proliferation. HER2 is generally neither overexpressed nor amplified [22]. When compared with invasive carcinoma of no special type, tubular carcinoma is more likely to be diagnosed at older age and be smaller in size. Nodal involvement is reported in the range of 4%–17%. The prognosis of patients with tubular carcinoma is very good. The largest series so far encompasses 444 patients with tubular carcinoma [19]. The 5-year disease-free survival (DFS) and OS were 94% and 88%, respectively, for tubular carcinoma versus 80% and 77%, respectively, for carcinoma “not otherwise specified”. More interestingly, the 5-year OS was similar to age-matched female sets from the general population.

Invasive cribriform carcinomas (ICCs) account for 0.1%–0.6% of breast cancers and are characterized by an invasive component showing a predominantly cribriform pattern [23]. The median age at diagnosis is 54–63 years [23, 24]. These tumors are subdivided into pure and mixed. In pure ICCs, the growth pattern is cribriform in more than 90% of the lesion. ICCs with a cribriform pattern and a limited extent of tubular invasive elements (less than 50%) are included in pure subtype. Mixed ICCs also contain areas of less-well-differentiated invasive carcinoma [25]. ICCs are generally estrogen receptor-positive (ER+), low grade, and low proliferating. Axillary lymph-nodal metastases are reported in approximately 10% of the cases [26]. ICC has an excellent prognosis in its pure form, whereas more caution is needed for the mixed variants.

Neuroendocrine carcinomas of the breast are defined by the diffuse expression of neuroendocrine markers along with the presence of morphologic neuroendocrine features. The WHO classification describes three main histologic types: neuroendocrine tumor, well-differentiated neuroendocrine carcinoma, and poorly differentiated/small cell and invasive breast carcinoma with neuroendocrine differentiation [2, 27]. The prevalence of the well-differentiated neuroendocrine tumor is up to 0.5% of breast cancers [28]. With IHC, synaptophysin or chromogranin must be expressed in >50% of the cells. These tumors are generally low-grade ER+, and

PgR+, and HER2-, with favorable prognosis [29]. The high-grade small-cell variant is described among the poor prognostic group.

Typically Hormone Receptor Negative

Medullary carcinoma represents less than 2% of breast carcinoma and occurs more frequently in younger women [1]. It is composed of poorly differentiated cells, with large vesicular nuclei and prominent nucleoli, arranged in syncytial architecture with circumscribed margins. The distinctive feature is a prominent lymphocytic infiltrate, both within the tumor and at the periphery [30, 31]. These features must be present in the entire tumor for the diagnosis of classical medullary carcinoma. Cases that do not fulfill all these criteria are defined as atypical medullary carcinoma or carcinoma with medullary features. The mammographic appearance is a mass with circumscribed margins; with sonography, medullary carcinoma generally appears as homogeneous or inhomogeneous hypoechoic mass with well-defined margins [32]. Magnetic resonance appearance is often indicative of a benign lesion [33].

Most of medullary cancer presents with triple-negative assets at immunohistochemistry, with cytokeratin 5/6 positivity [34, 35]. The majority of medullary carcinomas are aneuploid and highly proliferative. Despite these unfavorable histologic features, the prognosis of patients with medullary carcinoma is generally good. The medullary histotype is more common in the case of BRCA1 mutations. According to a study including more than 3,600 cases from the Breast Cancer Family Registry consortium, the prevalence of medullary histotype in BRCA1-associated tumors exceeds 16% [36].

The incidence of nodal involvement is lower than other carcinomas of the breast. In a case series including 46 cases, the 10-year-distant relapse-free survival reached 95% [34].

Adenoid cystic carcinoma of the breast is very rare, accounting for less than 1% of breast cancers. Adenoid cystic carcinoma predominantly affects postmenopausal women, with a median age at diagnosis of 60 years [37]. Morphologically, these tumors are similar to adenoid cystic carcinomas arising in the salivary glands, showing epithelial cells and myoepithelial cells arranged in tubular and cribriform architecture. The mitotic activity is generally low.

Mammographically, adenoid cystic carcinoma presents as either irregular masses or growing asymmetric densities, with minimal vascularity on color Doppler imaging [38]. Lymph-nodal involvement is reported in 0%–8% of the cases in the largest published series [39]. With IHC, these tumors are generally HR- and HER2- [40]. The prognosis is generally good, with 10-year OS exceeding 90% [41, 42]. Metastases are rare and generally spread many years after diagnosis, independently from axillary nodal involvement at initial diagnosis. The lung is one of the most frequent sites of distant recurrence. However, even in the presence of local or distant recurrence, patients have a prolonged and indolent clinical course [37].

This extremely rare tumor is one of the salivary gland-like tumors of the breast. At imaging, it appears as a well-circumscribed mass. This tumor generally lacks the expression of hormone receptors and HER2. A positive stain for epithelial membrane antigen and S100 protein is frequently reported

[43]. This tumor is generally described as having a good prognosis. However, a note of caution is required, taking into account the paucity of available data.

Also known as juvenile carcinoma, secretory breast carcinoma is extremely rare, representing 0.1%–0.2% of all breast cancers. It accounts for most of the breast cancers diagnosed in childhood. The distinctive pathological characteristics are intracellular or extracellular secretion and granular eosinophilic material [44]. The median age at diagnosis is 25–40 years [45, 46]. The ultrasonography (US) appearance generally resembles a benign lesion [47].

Secretory breast cancers are usually ER-, PgR-, and HER2-negative and have low Ki67 expression. These tumors generally harbor the t(12;15)ETV6-NTRK3 translocation [48]. The ETV-NTRK fusion results in the expression of a functional tyrosine kinases with potent transforming activity. Secretory carcinoma is associated with a good prognosis. Few metastatic cases are described; recurrences generally occurred after very prolonged disease-free intervals (12–20 years) [49].

Intermediate Prognosis

Apocrine Carcinoma

The apocrine epithelium is a normal constituent of apocrine glands, consisting of cells with eosinophilic cytoplasm and a large nucleus located near the base of the cell [50]. Apocrine phenotype is observed in a spectrum of breast epithelial lesions, ranging from benign metaplasia to apocrine carcinoma. The incidence of apocrine carcinoma is reported in the range of 0.3%–4% of all cases, mostly because of the lack of uniform criteria for its diagnosis. The more stringent definition considers as apocrine carcinoma only those neoplasms composed entirely or predominantly of apocrine-type epithelium [51]. Pure apocrine carcinomas are generally ER- and progesterone receptor (PgR)-, and androgen receptor (AR) positive [52]. HER2 is overexpressed in up to 54% of the cases [53]. Mammographic presentation do not differ from that of ductal carcinoma. Conflicting data are available on the outcome of invasive apocrine carcinoma. Some studies report that the prognosis of apocrine carcinoma is the same with other types of breast carcinoma, with the outcome depending on grade, HER2, and hormone receptor expression. A recently published retrospective analysis has included more than 6,800 cases of infiltrating ductal carcinoma NST and 72 cases of apocrine carcinoma. In this study, apocrine carcinomas were subdivided in pure apocrine carcinoma (ER-, PgR-, AR+) and apocrine-like carcinoma (ER or PgR+, AR-) [54]. The diagnosis of pure apocrine carcinoma was independently correlated with a worse DFS, whereas infiltrating ductal carcinoma and apocrine-like BC showed similar outcomes. However, when considering only triple-negative breast cancers, the prognosis of the apocrine histotype was intermediate between the histotypes with the best outcome (like medullary carcinomas) and the ones determining the worst outcome (like metaplastic carcinomas) [55].

Poor-Prognosis Group

Pleomorphic Lobular Carcinoma

Pleomorphic lobular carcinoma is a very rare and aggressive variant of lobular carcinoma, accounting for <1% of all BCs

[56, 57]. Pleomorphic lobular carcinoma is characterized by a diffuse spreading pattern arranged in single lines similar to classic invasive lobular cancer. However, the pleomorphic variant is composed of cells with more evident nuclear atypia and pleomorphism [58].

Pleomorphic lobular carcinoma generally affects postmenopausal women [59]. Similarly to the classic variant, pleomorphic lobular carcinoma generally presents with hormone receptor expression and negative staining for E-cadherin. These tumors, however, show a more aggressive nature, evidenced by higher-grade cytological features, the presence of lymphovascular invasion, and a more advanced stage at presentation. HER2 is overexpressed in up to 30% of the cases. Pleomorphic lobular cancer shares the same radiological challenges of the classic lobular counterpart [60]. The more aggressive biological features account for the overall poorer prognosis as compared with classic lobular carcinoma, being the outcome of pleomorphic lobular cancer patients similar to high-grade, invasive ductal carcinoma patients [51].

Invasive Micropapillary Carcinoma

Invasive micropapillary carcinoma is characterized by extensive lymphatic vessel invasion [1, 61]. This feature accounts for the high propensity for nodal metastases, reported in up to 70% of the cases, as well as for the high incidence of early recurrences in skin and in the chest wall [62, 63]. Median age at diagnosis is 52.5 years. With mammography, invasive micropapillary carcinoma appears as high-density mass, generally with spiculated margins [64]. The expression of HR is reported in approximately two-thirds of the cases. A positive HER2 status is described in up to 50% of the cases. This subtype is associated with a poor prognosis. In a study including 98 cases of invasive micropapillary carcinoma, the 10-year OS was 48% [65].

Metaplastic Carcinoma

Metaplastic breast cancers are a heterogeneous group of tumors characterized by differentiation of the neoplastic epithelium into squamous or mesenchymal phenotype. Recently the WHO Working Group proposed this descriptive classification including squamous cell carcinoma, spindle cell carcinoma, metaplastic carcinoma with mesenchymal differentiation, and mixed metaplastic carcinoma. The metaplastic carcinoma group also includes low grade adenosquamous carcinomas and fibromatosis-like metaplastic carcinomas that are associated with more favorable prognosis [1]. The incidence of metaplastic breast carcinoma is in the range of 0.2%–0.6%, and the median age at presentation is 47–61 years [66–68].

A relatively high proportion of metaplastic carcinomas are diagnosed in Hispanic or black women [1, 4]. With mammography, metaplastic carcinoma usually appears as a round, lobular, oval lesion with a predominantly circumscribed, high-density mass. On US, metaplastic carcinoma may presents as having solid and cystic components and may be microlobulated [31, 69].

These tumors are generally poorly differentiated and ER-, PgR-, and HER2-negative, with high Ki67 and p53 positivity [4, 39]. The majority of metaplastic carcinomas are node-negative

but have a high potential for metastatic spread [4]. Up to 10% of the patients present with de novo metastatic disease, and local or distant relapse is reported in >50% of the cases [70]. The prognosis is poorer than that of triple-negative invasive ductal carcinoma [67]. In the study by Hennessy et al. [71] including exclusively the squamous-cell subtype, the median OS was 37 months. From the onset of distant metastasis, survival is generally less than 1 year [5, 72]. On the other hand, well-differentiated metaplastic carcinomas, which are extremely rare, are generally associated with a good prognosis.

High-Grade Small Cell Neuroendocrine Carcinoma

This subtype is similar to neuroendocrine tumors arising in the lung. The diagnosis requires the exclusion of a nonmammary primary. Similar to other neuroendocrine tumors, neuroendocrine markers must be expressed in at least 50% of the cells. The positivity of ER and PgR inversely correlates with the degree of differentiation. HER2 is typically negative [73]. These tumors are generally associated with an aggressive disease course.

GENOMIC FEATURES OF RARE BC HISTOLOGIES

The comprehensive evaluation of the genomic landscape of BC is one of the main goals of the current research. Only a few studies have focused on rare BC entities so far. The observation that rare BC histologies are more homogeneous at the transcriptome level than classic histologies suggests that a similar degree of homogeneity may be also found at the genomic level, thus representing a model to investigate cancer pathways (Fig. 2). Herein we summarize the most relevant data about genomic characterization of rare BC histologies.

Good-Prognosis Group

A recent work evaluated the genomic profiles of 59 BC samples of 10 special types [12]. The first relevant result was that samples of the same histology presented similar degrees of gene copy number variations. In addition to that, some of the special types with the best prognosis (adenoid cystic, mucinous, and tubular carcinomas with neuroendocrine features) presented the lowest levels of gene copy number changes. Similarly, typically low-grade BC special types such as adenoid cystic, mucinous, and carcinomas presented low levels of genomic instability and simplex genomic architectural patterns.

In regard to specific aberrations selectively present or absent in rare good-prognosis histologies, some examples can be proposed. Mucinous, neuroendocrine, and adenoid cystic BC special types lack 1q gains and 16q losses, which are hallmark features of low-grade invasive ductal carcinomas, thus suggesting that pathways driving the carcinogenesis of these rare entities may be unique [12, 74, 75]. In support of this hypothesis, mucinous carcinomas of the breast lack *PIK3CA* and *AKT1* mutations, which is in contrast with the high frequency (up to 45%) at which *PIK3CA* mutations occur in luminal BCs [76] (TCGA). Within the typically hormone receptor-negative good-prognosis BC special types, we can identify two main histologies for which specific fusion genes have been identified. Adenoid cystic BCs recurrently harbor the t(6;9)(q22–23;p23–24) translocation that leads to the formation of the *MYB-NFIB* fusion gene, which involves the

patients should be treated as having the usual BC histology. The metaplastic cancer shares the same indications of ductal histology. The 2013 St. Gallen consensus conference simply recommends endocrine therapy for endocrine-responsive “special histological types” (cribriform, tubular, and mucinous) and cytotoxic therapy for endocrine nonresponsive special types (apocrine, medullary, adenoid cystic, and metaplastic) [9]. It is reported that adenoid cystic carcinoma may not require adjuvant chemotherapy, in case of node negativity. As previously discussed, the rarity of these tumors impedes the buildup of a robust scientific evidence. Thus, it is assumed by current international guidelines that the same chemotherapy regimens used for common BC histotypes should also be proposed in case of uncommon histologies, when indicated. Such an indication, however, reflects the lack of prognostic data and does not necessarily recapitulate the intrinsic biological chemosensitivity of different BC histotypes. As reported in this review, most of the good-prognosis endocrine-sensitive rare histotypes usually belong to the Luminal A subtype, which tends to be chemoresistant. Indeed, in a retrospective study of more than 500 BC patients treated with conventional neoadjuvant chemotherapy, the clinicopathological response of BC of special type was significantly poorer. However, despite a low rate of response, the prognosis of mucinous and apocrine BC was good [82]. Therefore, the indication to administer potential toxic chemotherapy for rare BCs with very good prognosis should be carefully evaluated by balancing potential benefits and disadvantages. From this perspective, anthracycline-free schedules could represent an option. In regard to more aggressive rare BC histotypes, no data on specific chemotherapy regimens are available; thus, the same agents used for common BCs should be proposed. However, metaplastic BC deserves specific considerations. Small retrospective studies in the neoadjuvant and metastatic setting have shown that this heterogeneous BC entity is chemoresistant to conventional chemotherapy. In a small retrospective study by Chen et al. [83], only 18% of metaplastic BC patients showed a partial response to neoadjuvant chemotherapy, and only 8% of the patients responded to first-line chemotherapy in the metastatic setting. In this series, no patient responded to anthracycline-, vinorelbine-, or cyclophosphamide-based regimens. Similarly, the M.D. Anderson Cancer Center experience reported only a 10% complete response rate in patients with metaplastic BC undergoing neoadjuvant chemotherapy [84]. Some scattered evidence suggests that metaplastic breast cancer might benefit from chemotherapy tailored on the specific metaplastic differentiation of cancer cells. This assumption derives from the observation that the clinical behavior of metaplastic breast cancer seems to reflect the behavior of sarcomas (in case of spindle cell metaplastic breast cancer) or squamous cell carcinomas (in case of epidermoid metaplastic breast cancer). Indeed, sarcomatoid metaplastic BC patients often develop pulmonary metastasis, and squamous cell metaplastic BC is commonly associated with local relapses even after local radiotherapy. Sporadic responses to ifosfamide- and anthracycline-based chemotherapy and to platinum-based chemotherapy have been reported for sarcomatoid and epidermoid metaplastic BC, respectively [40, 71, 85].

Considering the recent results from prospective trials supporting the role of platinum salts for patients with triple-negative breast cancers, there is the rationale to consider the incorporation of such drugs in the treatment of early or advanced epidermoid metaplastic breast cancer.

It is assumed by current international guidelines that the same chemotherapy regimens used for common BC histotypes should also be proposed in case of uncommon histologies, when indicated. Such an indication, however, reflects the lack of prognostic data and does not necessarily recapitulate the intrinsic biological chemosensitivity of different BC histotypes.

From a biological perspective, the observation that metaplastic cancers may be enriched in cells with stem-like features may account for their resistance to therapy and metastatic potential [86]. On the basis of recent translational studies, there may be the rationale to test selective PI3K inhibitors for this particular BC subset. Moreover, some preclinical evidence also suggests that epidermal growth factor receptor may potentially represent a target for squamous cell metaplastic breast cancers [87].

CONCLUSION

The management of rare breast cancer histotypes represents a real challenge in daily clinical practice. Indeed, these entities are rare, and conducting prospective studies focused on rare breast cancers is unrealistic. Moreover, rare breast cancers represent distinct entities with different clinical behavior and response to treatment, suggesting that they might also be driven by few genomic specific events. From a biological perspective, rare BC histologies may represent discrete homogeneous molecular entities, suggesting that they might be also driven by few genomic specific events. Therefore, in-depth genomic evaluation of aggressive rare histologies might allow the identification of specific cancer pathways that may also be involved in the progression of more common histologies. A more comprehensive study of the clinical and genomic aspects of rare histological subtypes is needed to provide a more complete landscape of BC disease to support a more personalized treatment decision.

AUTHOR CONTRIBUTIONS

Conception/Design: Maria Vittoria Dieci, Enrico Orvieto, Massimo Dominici, PierFranco Conte, Valentina Guarneri

Provision of study material or patients: Maria Vittoria Dieci, Enrico Orvieto, Massimo Dominici, PierFranco Conte, Valentina Guarneri

Collection and/or assembly of data: Maria Vittoria Dieci, Enrico Orvieto, Massimo Dominici, PierFranco Conte, Valentina Guarneri

Data analysis and interpretation: Maria Vittoria Dieci, Enrico Orvieto, Massimo Dominici, PierFranco Conte, Valentina Guarneri

Manuscript writing: Maria Vittoria Dieci, Enrico Orvieto, Massimo Dominici, PierFranco Conte, Valentina Guarneri

Final approval of manuscript: Maria Vittoria Dieci, Enrico Orvieto, Massimo Dominici, PierFranco Conte, Valentina Guarneri

DISCLOSURES

The authors indicated no financial relationships.

REFERENCES

1. Tavassoli FA, Devilee P. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon, France: IARC Press, 2003.
2. Lakhani SR, Ellis IO, Schnitt SJ et al. WHO Classification of Tumors of the Breast. Lyon, France: IARC, 2012.
3. Northridge ME, Rhoads GG, Wartenberg D et al. The importance of histologic type on breast cancer survival. *J Clin Epidemiol* 1997;50:283–290.
4. Rakha EA, Lee AH, Evans AJ et al. Tubular carcinoma of the breast: Further evidence to support its excellent prognosis. *J Clin Oncol* 2010;28:99–104.
5. Luini A, Aguilar M, Gatti G et al. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: The experience of the European Institute of Oncology and review of the literature. *Breast Cancer Res Treat* 2007;101:349–353.
6. Perou CM, Sørli T, Eisen MB et al. Molecular portraits of human breast tumours. *Nature* 2000;406:747–752.
7. Prat A, Parker JS, Karginova O et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. *Breast Cancer Res* 2010;12:R68.
8. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. *Mol Oncol* 2011;5:5–23.
9. Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Ann Oncol* 2013;24:2206–2223.
10. Curtis C, Shah SP, Chin SF et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* 2012;486:346–352.
11. Weigelt B, Horlings HM, Kreike B et al. Refinement of breast cancer classification by molecular characterization of histological special types. *J Pathol* 2008;216:141–150.
12. Horlings HM, Weigelt B, Anderson EM et al. Genomic profiling of histological special types of breast cancer. *Breast Cancer Res Treat* 2013;142:257–269.
13. Capella C, Eusebi V, Mann B et al. Endocrine differentiation in mucoid carcinoma of the breast. *Histopathology* 1980;4:613–630.
14. Clayton F. Pure mucinous carcinomas of breast: Morphologic features and prognostic correlates. *Hum Pathol* 1986;17:34–38.
15. Silverberg SG, Kay S, Chitale AR et al. Colloid carcinoma of the breast. *Am J Clin Pathol* 1971;55:355–363.
16. Tan PH, Tse GMK, Bay BH. Mucinous breast lesions: Diagnostic challenges. *J Clin Pathol* 2008;61:11–19.
17. Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. *Breast Cancer Res Treat* 2008;111:541–547.
18. Norris HJ, Taylor HB. Prognosis of mucinous (gelatinous) carcinoma of the breast. *Cancer* 1965;18:879–885.
19. Memis A, Ozdemir N, Parildar M et al. Mucinous (colloid) breast cancer: Mammographic and US features with histologic correlation. *Eur J Radiol* 2000;35:39–43.
20. Diab SG, Clark GM, Osborne CK et al. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. *J Clin Oncol* 1999;17:1442–1448.
21. Günhan-Bilgen I, Oktay A. Tubular carcinoma of the breast: Mammographic, sonographic, clinical and pathologic findings. *Eur J Radiol* 2007;61:158–162.
22. Oakley GJ 3rd, Tubbs RR, Crowe J et al. HER-2 amplification in tubular carcinoma of the breast. *Am J Clin Pathol* 2006;126:55–58.
23. Louwman MW, Vrienen M, van Beek MW et al. Uncommon breast tumors in perspective: Incidence, treatment and survival in the Netherlands. *Int J Cancer* 2007;121:127–135.
24. Stutz JA, Evans AJ, Pinder S et al. The radiological appearances of invasive cribriform carcinoma of the breast. *Clin Radiol* 1994;49:693–695.
25. Page DL, Dixon JM, Anderson TJ et al. Invasive cribriform carcinoma of the breast. *Histopathology* 1983;7:525–536.
26. Venable JG, Schwartz AM, Silverberg SG. Infiltrating cribriform carcinoma of the breast: A distinctive clinicopathologic entity. *Hum Pathol* 1990;21:333–338.
27. Righi L, Sapino A, Marchiò C et al. Neuroendocrine differentiation in breast cancer: Established facts and unresolved problems. *Semin Diagn Pathol* 2010;27:69–76.
28. López-Bonet E, Alonso-Ruano M, Barraza G et al. Solid neuroendocrine breast carcinomas: Incidence, clinico-pathological features and immunohistochemical profiling. *Oncol Rep* 2008;20:1369–1374.
29. Sapino A, Papotti M, Righi L et al. Clinical significance of neuroendocrine carcinoma of the breast. *Ann Oncol* 2001;12(suppl 2):S115–S117.
30. Ridolfi RL, Rosen PP, Port A et al. Medullary carcinoma of the breast: A clinicopathologic study with 10 year follow-up. *Cancer* 1977;40:1365–1385.
31. Liberman L, LaTrenta LR, Samli B et al. Overdiagnosis of medullary carcinoma: A mammographic-pathologic correlative study. *Radiology* 1996;201:443–446.
32. Karan B, Pourbagher A, Bolat FA. Unusual malignant breast lesions: Imaging-pathological correlations. *Diagn Interv Radiol* 2012;18:270–276.
33. Majid AS, de Paredes ES, Doherty RD et al. Missed breast carcinoma: Pitfalls and pearls. *Radiographics* 2003;23:881–895.
34. Vu-Nishino H, Tavassoli FA, Ahrens WA et al. Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT). *Int J Radiat Oncol Biol Phys* 2005;62:1040–1047.
35. Vincent-Salomon A, Gruel N, Lucchesi C et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. *Breast Cancer Res* 2007;9:R24.
36. Work ME, Andrulis IL, John EM et al. Risk factors for uncommon histologic subtypes of breast cancer using centralized pathology review in the Breast Cancer Family Registry. *Breast Cancer Res Treat* 2012;134:1209–1220.
37. Vranic S, Bender R, Palazzo J et al. A review of adenoid cystic carcinoma of the breast with emphasis on its molecular and genetic characteristics. *Hum Pathol* 2013;44:301–309.
38. Glazebrook KN, Reynolds C, Smith RL et al. Adenoid cystic carcinoma of the breast. *AJR Am J Roentgenol* 2010;194:1391–1396.
39. Arpino G, Clark GM, Mohsin S et al. Adenoid cystic carcinoma of the breast: Molecular markers, treatment, and clinical outcome. *Cancer* 2002;94:2119–2127.
40. Cadoo KA, McArdle O, O'Shea AM et al. Management of unusual histological types of breast cancer. *The Oncologist* 2012;17:1135–1145.
41. Thompson K, Grabowski J, Saltzstein SL et al. Adenoid cystic breast carcinoma: Is axillary staging necessary in all cases? Results from the California Cancer Registry. *Breast J* 2011;17:485–489.
42. Ghabach B, Anderson WF, Curtis RE et al. Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): A population-based cohort study. *Breast Cancer Res* 2010;12:R54.
43. Peintinger F, Leibl S, Reitsamer R et al. Primary acinic cell carcinoma of the breast: A case report with long-term follow-up and review of the literature. *Histopathology* 2004;45:645–648.
44. Tixier H, Picard A, Guiu S et al. Long-term recurrence of secretory breast carcinoma with metastatic sentinel lymph nodes. *Arch Gynecol Obstet* 2011;283(suppl 1):77–78.
45. Ozguroglu M, Tascilar K, Ilvan S et al. Secretory carcinoma of the breast: Case report and review of the literature. *Oncology* 2005;68:263–268.
46. Vieni S, Cabibi D, Cipolla C et al. Secretory breast carcinoma with metastatic sentinel lymph node. *World J Surg Oncol* 2006;4:88.
47. Mun SH, Ko EY, Han BK et al. Secretory carcinoma of the breast: Sonographic features. *J Ultrasound Med* 2008;27:947–954.
48. Tognon C, Knezevich SR, Huntsman D et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. *Cancer Cell* 2002;2:367–376.
49. Herz H, Cooke B, Goldstein D. Metastatic secretory breast cancer. Non-responsiveness to chemotherapy: Case report and review of the literature. *Ann Oncol* 2000;11:1343–1347.
50. Zagorianakou P, Zagorianakou N, Stefanou D et al. The enigmatic nature of apocrine breast lesions. *Virchows Arch* 2006;448:525–531.
51. Rosen PP. Rosen's Breast Pathology. Philadelphia, PA: Lippincott Williams & Wilkins, 2001.
52. Japaze H, Emina J, Diaz C et al. "Pure" invasive apocrine carcinoma of the breast: A new clinicopathological entity? *Breast* 2005;14:3–10.
53. Vranic S, Tawfik O, Palazzo J et al. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. *Mod Pathol* 2010;23:644–653.
54. Dellapasqua S, Maisonneuve P, Viale G et al. Immunohistochemically defined subtypes and outcome of apocrine breast cancer. *Clin Breast Cancer* 2013;13:95–102.
55. Montagna E, Maisonneuve P, Rotmensz N et al. Heterogeneity of triple-negative breast cancer: Histologic subtyping to inform the outcome. *Clin Breast Cancer* 2013;13:31–39.
56. Weidner N, Semple JP. Pleomorphic variant of invasive lobular carcinoma of the breast. *Hum Pathol* 1992;23:1167–1171.

57. Butler D, Rosa M. Pleomorphic lobular carcinoma of the breast: A morphologically and clinically distinct variant of lobular carcinoma. *Arch Pathol Lab Med* 2013;137:1688–1692.
58. Eusebi V, Magalhaes F, Azzopardi JG. Pleomorphic lobular carcinoma of the breast: An aggressive tumor showing apocrine differentiation. *Hum Pathol* 1992;23:655–662.
59. Jacobs M, Fan F, Tawfik O. Clinicopathologic and biomarker analysis of invasive pleomorphic lobular carcinoma as compared with invasive classic lobular carcinoma: An experience in our institution and review of the literature. *Ann Diagn Pathol* 2012;16:185–189.
60. Jung HN, Shin JH, Han BK et al. Are the imaging features of the pleomorphic variant of invasive lobular carcinoma different from classic ILC of the breast? *Breast* 2013;22:324–329.
61. Pettinato G, Manivel CJ, Panico L et al. Invasive micropapillary carcinoma of the breast: Clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. *Am J Clin Pathol* 2004;121:857–866.
62. Zekioglu O, Erhan Y, Ciris M et al. Invasive micropapillary carcinoma of the breast: High incidence of lymph node metastasis with extranodal extension and its immunohistochemical profile compared with invasive ductal carcinoma. *Histopathology* 2004;44:18–23.
63. Walsh MM, Bleiweiss JJ. Invasive micropapillary carcinoma of the breast: Eighty cases of an under-recognized entity. *Hum Pathol* 2001;32:583–589.
64. Günhan-Bilgen I, Zekioglu O, Ustün EE et al. Invasive micropapillary carcinoma of the breast: Clinical, mammographic, and sonographic findings with histopathologic correlation. *AJR Am J Roentgenol* 2002;179:927–931.
65. Chen L, Fan Y, Lang RG et al. Breast carcinoma with micropapillary features: Clinicopathologic study and long-term follow-up of 100 cases. *Int J Surg Pathol* 2008;16:155–163.
66. Pezzi CM, Patel-Parekh L, Cole K et al. Characteristics and treatment of metaplastic breast cancer: Analysis of 892 cases from the National Cancer Data Base. *Ann Surg Oncol* 2007;14:166–173.
67. Jung SY, Kim HY, Nam BH et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. *Breast Cancer Res Treat* 2010;120:627–637.
68. Al Sayed AD, El Weshi AN, Tulbah AM et al. Metaplastic carcinoma of the breast clinical presentation, treatment results and prognostic factors. *Acta Oncol* 2006;45:188–195.
69. Günhan-Bilgen I, Memiş A, Ustün EE et al. Metaplastic carcinoma of the breast: Clinical, mammographic, and sonographic findings with histopathologic correlation. *AJR Am J Roentgenol* 2002;178:1421–1425.
70. Yerushalmi R, Hayes MM, Gelmon KA. Breast carcinoma: Rare types: Review of the literature. *Ann Oncol* 2009;20:1763–1770.
71. Hennessy BT, Krishnamurthy S, Giordano S et al. Squamous cell carcinoma of the breast. *J Clin Oncol* 2005;23:7827–7835.
72. Tse GM, Tan PH, Putti TC et al. Metaplastic carcinoma of the breast: A clinicopathological review. *J Clin Pathol* 2006;59:1079–1083.
73. Alkaied H, Harris K, Azab B et al. Primary neuroendocrine breast cancer, how much do we know so far? *Med Oncol* 2012;29:2613–2618.
74. Lacroix-Triki M, Suarez PH, MacKay A et al. Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. *J Pathol* 2010;222:282–298.
75. Wetterskog D, Lopez-Garcia MA, Lambros MB et al. Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. *J Pathol* 2012;226:84–96.
76. Kehr EL, Jorns JM, Ang D et al. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations. *Hum Pathol* 2012;43:2207–2212.
77. Dieci MV, Lefebvre C, Scott V et al. Whole exome sequencing of rare aggressive breast cancer histologies reveal novel pathways for breast cancer progression. Paper presented at: 2013 San Antonio Breast Cancer Symposium, December 10–14, 2013; San Antonio, TX. Abstract 798.
78. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. *Nature* 2012;490:61–70.
79. Natrajan R, Wilkerson PM, Marchiò C et al. Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. *J Pathol* 2014;232:553–565.
80. Vo T, Xing Y, Meric-Bernstam F et al. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. *Am J Surg* 2007;194:527–531.
81. NCCN Clinical Practice Guidelines in Oncology. NCCN Guidelines, Breast Cancer v1.2014. Available at http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed February 27, 2014.
82. Nagao T, Kinoshita T, Hojo T et al. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: The relationship between the outcome and the clinicopathological characteristics. *Breast* 2012;21:289–295.
83. Chen IC, Lin CH, Huang CS et al. Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. *Breast Cancer Res Treat* 2011;130:345–351.
84. Hennessy BT, Giordano S, Broglio K et al. Biphasic metaplastic sarcomatoid carcinoma of the breast. *Ann Oncol* 2006;17:605–613.
85. Brown-Glaberman U, Graham A, Stopeck A. A case of metaplastic carcinoma of the breast responsive to chemotherapy with ifosfamide and etoposide: Improved antitumor response by targeting sarcomatous features. *Breast J* 2010;16:663–665.
86. Hennessy BT, Gonzalez-Angulo A-M, Stemke-Hale K et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. *Cancer Res* 2009;69:4116–4124.
87. Kimura F, Iwaya K, Kawaguchi T et al. Epidermal growth factor-dependent enhancement of invasiveness of squamous cell carcinoma of the breast. *Cancer Sci* 2010;101:1133–1140.

CME

This article is available for continuing medical education credit at CME.TheOncologist.com.